Karyopharm reports interim data from eltanexor Phase I/II study

Karyopharm Therapeutics has reported interim data from the Phase II portion of its open-label Phase I/II trial of single-agent eltanexor (KPT-8602) for the treatment of higher relapsed/refractory myelodysplastic neoplasms.